Multiplying the concentrations of both biomarkers (i.e., [TIMP-2]•[IGFBP7]) yields an AKI risk score, with a score >0.3 (ng/ml)2/1000 having 92% sensitivity and 46% specificity while a score >2.0 (ng/ml)2/1000 has 37% sensitivity and 95% specificity for the occurrence of AKI stage 2–3 [55]. Here, IGFBP7 is linked to acute kidney injury.